Search Patents
  • Publication number: 20160130231
    Abstract: The invention relates to ROR modulators; compositions comprising an effective amount of a ROR modulator; and methods for treating or preventing diseases associated with ROR.
    Type: Application
    Filed: January 5, 2016
    Publication date: May 12, 2016
    Inventors: Anderson Gaweco, Jefferson W. Tilley, John Walker, Samantha Palmer, James Blinn
  • Publication number: 20040092529
    Abstract: The present invention relates to compounds of the formula I 1
    Type: Application
    Filed: October 16, 2003
    Publication date: May 13, 2004
    Applicant: Pfizer Inc
    Inventors: Laura C. Blumberg, Matthew F. Brown, Anderson S. Gaweco, Ronald P. Gladue, Matthew M. Hayward, Gregory D. Lundquist, Christopher S. Poss, Andrei Shavnya
  • Publication number: 20040116441
    Abstract: The present invention relates to methods of using CCR1 antagonists as immunomodulatory agents.
    Type: Application
    Filed: October 16, 2003
    Publication date: June 17, 2004
    Applicant: Pfizer Inc
    Inventors: Matthew F. Brown, Anderson S. Gaweco, Ronald P. Gladue, Matthew M. Hayward
  • Publication number: 20150073016
    Abstract: The invention relates to ROR modulators; compositions comprising an effective amount of a ROR modulator; and methods for treating or preventing diseases associated with ROR.
    Type: Application
    Filed: April 30, 2013
    Publication date: March 12, 2015
    Inventors: Anderson GAWECO, Jefferson TILLEY, John WALKER, Samantha PALMER, James BLINN
  • Publication number: 20040097554
    Abstract: The present invention relates to compounds of the formula (I) 1
    Type: Application
    Filed: October 16, 2003
    Publication date: May 20, 2004
    Applicant: Pfizer Inc
    Inventors: Matthew F. Brown, Anderson S. Gaweco, Ronald P. Gladue, John C. Kath, Christopher S. Poss
  • Publication number: 20150099779
    Abstract: The invention relates to ROR modulators; compositions comprising an effective amount of a ROR modulator; and methods for treating or preventing diseases associated with ROR.
    Type: Application
    Filed: April 30, 2013
    Publication date: April 9, 2015
    Inventors: Anderson Gaweco, Jefferson W. Tilley, John Walker, Samantha Palmer, James Blinn
  • Patent number: 9447069
    Abstract: The invention relates to ROR modulators; compositions comprising an effective amount of a ROR modulator; and methods for treating or preventing diseases associated with ROR.
    Type: Grant
    Filed: April 30, 2013
    Date of Patent: September 20, 2016
    Assignee: INNOV17 LLC
    Inventors: Anderson Gaweco, Jefferson W. Tilley, John Walker, Samantha Palmer, James Blinn
  • Publication number: 20150065480
    Abstract: The invention relates to MIF inhibitors; compositions comprising an effective amount of a MIF inhibitor; and methods for treating or preventing diseases associated with MIF.
    Type: Application
    Filed: April 13, 2012
    Publication date: March 5, 2015
    Applicant: INNOVIMMUNE BIOTHERAPEUTICS, INC.
    Inventors: Anderson Gaweco, John Walker, Joseph B. Monahan, Jerry W. Cubbage, Jeffery Carroll
  • Patent number: 9708268
    Abstract: The invention relates to ROR modulators; compositions comprising an effective amount of a ROR modulator; and methods for treating or preventing diseases associated with ROR.
    Type: Grant
    Filed: April 30, 2013
    Date of Patent: July 18, 2017
    Assignee: INNOV17 LLC
    Inventors: Anderson Gaweco, Jefferson W. Tilley, John Walker, Samantha Palmer, James Blinn
  • Patent number: 9050334
    Abstract: The invention relates to MIF inhibitors; compositions comprising an effective amount of a MIF inhibitor; and methods for treating or preventing diseases associated with MIF.
    Type: Grant
    Filed: July 15, 2011
    Date of Patent: June 9, 2015
    Assignee: INNOV88 LLC
    Inventors: Anderson Gaweco, John K. Walker, Joseph B. Monahan, Jerry W. Cubbage, Jeffery Carroll
  • Patent number: 9133164
    Abstract: The invention relates to MIF inhibitors; compositions comprising an effective amount of a MIF inhibitor; and methods for treating or preventing diseases associated with MIF.
    Type: Grant
    Filed: April 13, 2012
    Date of Patent: September 15, 2015
    Assignee: INNOV88 LLC
    Inventors: Anderson Gaweco, John Walker, Joseph B. Monahan, Jerry W. Cubbage, Jeffery Carroll
  • Publication number: 20150252051
    Abstract: Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of Retinoic Acid Receptor-Related Orphan Receptor regulated diseases and disorders.
    Type: Application
    Filed: March 9, 2015
    Publication date: September 10, 2015
    Inventors: Anderson Gaweco, Jefferson Tilley, James Blinn
  • Publication number: 20150252022
    Abstract: Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of Retinoic Acid Receptor-Related Orphan Receptor regulated diseases and disorders.
    Type: Application
    Filed: March 9, 2015
    Publication date: September 10, 2015
    Inventors: Anderson Gaweco, Jefferson Tilley, James Blinn
  • Publication number: 20160024086
    Abstract: Provided herein are compounds of the formulas (I) and (II): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of Retinoic Acid Receptor-Related Orphan Receptor regulated diseases and disorders.
    Type: Application
    Filed: July 24, 2015
    Publication date: January 28, 2016
    Inventors: Anderson Gaweco, Jefferson Tilley, James Blinn
  • Publication number: 20050137684
    Abstract: Delivery of a Janus Kinase 3 (JAK3) inhibitor locally, particularly from an intravascular stent, directly from micropores in the stent body or mixed or bound to a polymer coating applied on stent, to inhibit neointimal tissue proliferation and thereby prevent restenosis.
    Type: Application
    Filed: December 13, 2004
    Publication date: June 23, 2005
    Inventors: Paul Changelian, Anderson Gaweco
  • Publication number: 20050137679
    Abstract: Delivery of Janus Kinase 3 (JAK3) inhibitor locally, particularly from an intravascular stent, directly from micropores in the stent body or mixed or bound to a polymer coating applied on stent, to inhibit neointimal tissue proliferation and thereby prevent restenosis. This invention facilitates the performance of the stent in inhibiting restonosis.
    Type: Application
    Filed: December 13, 2004
    Publication date: June 23, 2005
    Inventors: Paul Changelian, Anderson Gaweco
  • Publication number: 20170158669
    Abstract: Provided herein are compounds of the formulas (I) and (II): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of Retinoic Acid Receptor-Related Orphan Receptor regulated diseases and disorders.
    Type: Application
    Filed: July 24, 2015
    Publication date: June 8, 2017
    Inventors: Anderson Gaweco, Jefferson Tilley, James Blinn
  • Publication number: 20160024052
    Abstract: Provided herein are compounds of the formulas (I) and (II): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of Retinoic Acid Receptor-Related Orphan Receptor regulated diseases and disorders.
    Type: Application
    Filed: July 24, 2015
    Publication date: January 28, 2016
    Inventors: Anderson Gaweco, Jefferson Tilley, James Blinn
  • Publication number: 20160024056
    Abstract: Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of Retinoic Acid Receptor-Related Orphan Receptor regulated diseases and disorders.
    Type: Application
    Filed: July 24, 2015
    Publication date: January 28, 2016
    Inventors: Anderson Gaweco, Jefferson Tilley, James Blinn
  • Publication number: 20160024057
    Abstract: Provided herein are compounds of the formulas (I) and (II): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of Retinoic Acid Receptor-Related Orphan Receptor regulated diseases and disorders.
    Type: Application
    Filed: July 24, 2015
    Publication date: January 28, 2016
    Inventors: Anderson Gaweco, Jefferson Tilley, James Blinn
Narrow Results

Filter by US Classification